Metabolic/Obesity Phase 1 Deal Benchmarks — Europe (2026)
Median upfront of $57M with total deal values reaching $650M in Europe territory.
Median Upfront
$57M
Total Deal Value
$448M
Royalty Range
6.1%–11.5%
Territory Multiplier
0.25x
Understanding Metabolic/Obesity Deal Benchmarks at Phase 1
Phase 1 Metabolic/Obesity licensing deals in Europe territory command a median upfront payment of $57M, with values ranging from $27M at the low end to $88M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the metabolic/obesity therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $246M to $650M, with a median of $448M. Royalty rates for metabolic/obesity assets at this stage typically fall between 6.1% and 11.5% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Europe territory applies a 0.25x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating europe rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $27M | $57M | $88M |
| Total Deal Value | $246M | $448M | $650M |
| Royalty Rate | 6.1% | — | 11.5% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2021 | Xeris Pharmaceuticals | Tetris Pharma | $0M | $71M | reformulation |
See All Comparable Deals
View 1 comparable Metabolic/Obesity transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 1 Metabolic/Obesity deals in Europe territory?
How does Europe territory affect Metabolic/Obesity deal value?
What royalty rates are typical for Phase 1 Metabolic/Obesity licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$19M upfront
Metabolic/Obesity · Preclinical · Europe
$147M upfront
Metabolic/Obesity · Phase 2 · Europe
$308M upfront
Metabolic/Obesity · Phase 3 · Europe
$871M upfront
Metabolic/Obesity · Approved · Europe
$22M upfront
Oncology · Phase 1 · Europe
$19M upfront
Neurology/CNS · Phase 1 · Europe
$41M upfront
Immunology · Phase 1 · Europe
$229M upfront
Metabolic/Obesity · Phase 1 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Metabolic/Obesity Phase 1 Deal Benchmarks — Europe (2026). Retrieved from https://solidus.ambrosiaventures.co/data/metabolic-phase-1-deals-europe
<a href="https://solidus.ambrosiaventures.co/data/metabolic-phase-1-deals-europe">Metabolic/Obesity Phase 1 Deal Benchmarks — Europe (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=metabolic&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.